News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
710,989 Results
Type
Article (43627)
Company Profile (345)
Press Release (667017)
Section
Business (212064)
Career Advice (2164)
Deals (37061)
Drug Delivery (102)
Drug Development (84088)
Employer Resources (173)
FDA (16635)
Job Trends (15542)
News (359548)
Policy (34426)
Tag
Academia (2616)
Alliances (51703)
Alzheimer's disease (1242)
Approvals (16541)
Artificial intelligence (129)
Bankruptcy (369)
Best Places to Work (11675)
Biotechnology (218)
Breast cancer (104)
Cancer (939)
Cardiovascular disease (83)
Career advice (1803)
Cell therapy (203)
Clinical research (66471)
Collaboration (332)
Compensation (161)
COVID-19 (2615)
Data (843)
Diabetes (138)
Diagnostics (6210)
Drug pricing (94)
Earnings (86243)
Employer resources (152)
Events (112897)
Executive appointments (247)
FDA (17075)
Funding (295)
Gene therapy (160)
GLP-1 (624)
Government (4525)
Healthcare (18997)
Infectious disease (2694)
Inflammatory bowel disease (107)
Interviews (338)
IPO (16709)
Job creations (4165)
Job search strategy (1551)
Layoffs (444)
Legal (8493)
Lung cancer (171)
Manufacturing (161)
Medical device (13287)
Medtech (13292)
Mergers & acquisitions (20348)
Metabolic disorders (397)
Neuroscience (1496)
NextGen Class of 2024 (6716)
Non-profit (4542)
Northern California (1189)
Obesity (240)
Opinion (219)
Patents (101)
People (58611)
Pharmaceutical (101)
Phase I (20622)
Phase II (29199)
Phase III (21920)
Pipeline (205)
Postmarket research (2686)
Preclinical (8719)
Radiopharmaceuticals (244)
Rare diseases (193)
Real estate (6352)
Regulatory (22649)
Research institute (2388)
Resumes & cover letters (371)
Southern California (1070)
Startups (3782)
United States (11683)
Vaccines (564)
Weight loss (197)
Date
Last 7 days (791)
Last 30 days (2731)
Last 365 days (36554)
2024 (30968)
2023 (40965)
2022 (52147)
2021 (56705)
2020 (55143)
2019 (47875)
2018 (36191)
2017 (33608)
2016 (33231)
2015 (39088)
2014 (33052)
2013 (28153)
2012 (30208)
2011 (30908)
2010 (28935)
Location
Africa (806)
Arizona (195)
Asia (40957)
Australia (6498)
California (2705)
Canada (1174)
China (214)
Colorado (117)
Connecticut (121)
Europe (87479)
Florida (390)
Georgia (98)
Illinois (317)
Indiana (186)
Kansas (95)
Maryland (520)
Massachusetts (2216)
Michigan (143)
Minnesota (248)
New Jersey (823)
New York (830)
North Carolina (700)
Northern California (1189)
Ohio (125)
Pennsylvania (741)
South America (1181)
Southern California (1070)
Texas (385)
Washington State (324)
710,989 Results for "ns pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
NS Pharma Shares Preliminary Results of Viltolarsen (NS-065 / NCNP-01) Phase 3 Clinical Trial (RACER53 Study)
NS Pharma, Inc., a subsidiary of Nippon Shinyaku Co., Ltd., announced that it has received preliminary analysis results from the global Phase 3 clinical trial of NS-065/NCNP-01.
May 27, 2024
·
6 min read
Pharm Country
NS Pharma, Inc. Shares New VILTEPSO® (Viltolarsen) Data at the MDA Clinical & Scientific Conference 2024
NS Pharma, Inc. (NS Pharma) is excited to announce participation in the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Orlando, Florida, March 3 – 6.
March 6, 2024
·
4 min read
Drug Development
NS Pharma’s DMD Candidate Viltespo Fails Confirmatory Phase III Trial
NS Pharma, a subsidiary of Nippon Shinyaku, announced Monday that its Duchenne muscular dystrophy candidate Viltepso failed a late-stage confirmatory trial, showing no significant motor function improvements over placebo.
May 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NS Pharma’s Galactic53 Trial Data Is Published in Scientific Reports
October 16, 2024
·
5 min read
Business
NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System
NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) – headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics – headquartered in London, United Kingdom, to develop nucleic acid drugs for the potential treatment of intractable and rare diseases of the central nervous system.
April 4, 2024
·
2 min read
Pharm Country
The European Commission Grants Orphan Drug Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd, announced today that the European Commission (EC) has granted orphan drug designation to NS-229, which is being developed for the treatment of the rare disease eosinophilic granulomatosis with polyangiitis (EGPA).
January 22, 2024
·
1 min read
Pharm Country
NS Pharma Unveils Duchenne Heroes, a Program to Inspire and Amplify the Voices of People Living with Duchenne Muscular Dystrophy
NS Pharma, Inc. announced the launch of Duchenne Heroes a program created to raise awareness and champion the voices of people affected by Duchenne muscular dystrophy.
November 21, 2023
·
3 min read
Press Releases
NS Pharma Appoints New President to Oversee Next Phases of Orphan Drug Clinical Development and Commercialization
July 11, 2024
·
1 min read
BioMidwest
C2N’s Precivity™ Tests are Now Offered Through Mayo Clinic Laboratories
C2N Diagnostics, LLC, which provides exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health, has entered into a non-exclusive agreement with Mayo Clinic Laboratories, for inclusion of C2N’s Precivity tests in Mayo Clinic Laboratories’ test offerings to its clients.
June 27, 2024
·
4 min read
Pharm Country
NS-089/NCNP-02 Receives Orphan Drug Designation from the European Commission for the Treatment of Duchenne Muscular Dystrophy
NS Pharma, Inc. has granted orphan drug designation for NS-089/NCNP-02, which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne).
December 21, 2023
·
2 min read
1 of 71,099
Next